These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38128174)

  • 1. Cancer risk with biologic and targeted synthetic DMARDs in patients with rheumatic diseases and previous malignancies: Results from the BIOBADASER register.
    Molina-Collada J; Alonso F; Otero L; Bohórquez C; Díaz Torné C; Pérez García C; Blanco Madrigal JM; Vela P; Álvaro-Gracia JM; Castrejón I;
    Semin Arthritis Rheum; 2024 Feb; 64():152341. PubMed ID: 38128174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of dementia in patients with rheumatoid arthritis and association with disease modifying anti-rheumatic drugs - Analysis of a national claims database.
    Sattui SE; Navarro-Millan I; Xie F; Rajan M; Yun H; Curtis JR
    Semin Arthritis Rheum; 2022 Dec; 57():152083. PubMed ID: 36155968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short- and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice.
    Huss V; Bower H; Wadström H; Frisell T; Askling J;
    Rheumatology (Oxford); 2022 May; 61(5):1810-1818. PubMed ID: 34324640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in Market Share of Biologic and Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs for Treatment of Rheumatoid Arthritis: Results from the Ontario Best-Practice Research Initiative Database.
    Hepworth E; Movahedi M; Rampakakis E; Mirza R; Lau A; Cesta A; Pope J; Sampalis JS; Bombardier C
    Curr Rheumatol Rev; 2021; 17(3):349-359. PubMed ID: 33308132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis.
    Silva-Fernández L; Lunt M; Kearsley-Fleet L; Watson KD; Dixon WG; Symmons DP; Hyrich KL;
    Rheumatology (Oxford); 2016 Nov; 55(11):2033-2039. PubMed ID: 27550304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs.
    Cho SK; Lee J; Han M; Bae SC; Sung YK
    Arthritis Res Ther; 2017 Dec; 19(1):277. PubMed ID: 29246243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Singapore Chapter of Rheumatologists updated consensus statement on the eligibility for government subsidization of biologic and targeted-synthetic therapy for the treatment of rheumatoid arthritis.
    Leong JWY; Cheung PP; Dissanayake S; Fong WWS; Leong KH; Leung YY; Lim AYN; Lui NL; Manghani M; Santosa A; Sriranganathan MK; Suresh E; Tan TC; Teng GG; Lahiri M
    Int J Rheum Dis; 2020 Feb; 23(2):140-152. PubMed ID: 31859424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study.
    Simon TA; Boers M; Hochberg M; Baker N; Skovron ML; Ray N; Singhal S; Suissa S; Gomez-Caminero A
    Arthritis Res Ther; 2019 Nov; 21(1):228. PubMed ID: 31703717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Systematic Review of the safety of non-TNF inhibitor biologic and targeted synthetic drugs in rheumatic disease in pregnancy.
    Nguyen H; Ahmed K; Luo W; Flint J; Giles I
    Semin Arthritis Rheum; 2021 Dec; 51(6):1205-1217. PubMed ID: 34689007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of major adverse cardiovascular events in patients with rheumatoid arthritis treated with conventional synthetic, biologic and targeted synthetic disease-modifying antirheumatic drugs: observational data from the German RABBIT register.
    Meissner Y; Schäfer M; Albrecht K; Kekow J; Zinke S; Tony HP; Strangfeld A
    RMD Open; 2023 Oct; 9(4):. PubMed ID: 37880180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT.
    Strangfeld A; Hierse F; Rau R; Burmester GR; Krummel-Lorenz B; Demary W; Listing J; Zink A
    Arthritis Res Ther; 2010; 12(1):R5. PubMed ID: 20064207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of rheumatoid arthritis and biologic and targeted synthetic disease modifying antirheumatic agents on cancer risk and recurrence.
    Singh N; Li CI
    Curr Opin Rheumatol; 2021 May; 33(3):292-299. PubMed ID: 33741804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland.
    Finckh A; Tellenbach C; Herzog L; Scherer A; Moeller B; Ciurea A; von Muehlenen I; Gabay C; Kyburz D; Brulhart L; Müller R; Hasler P; Zufferey P;
    RMD Open; 2020 May; 6(1):. PubMed ID: 32385143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Malignancy outcomes in patients with rheumatoid arthritis treated with abatacept and other disease-modifying antirheumatic drugs: Results from a 10-year international post-marketing study.
    Simon TA; Suissa S; Boers M; Hochberg MC; Skovron ML; Askling J; Michaud K; Strangfeld A; Pedro S; Frisell T; Meissner Y; Dominique A; Gomez A
    Semin Arthritis Rheum; 2024 Feb; 64():152240. PubMed ID: 37500379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Systematic Overview of Contraindications and Special Warnings for Biologic and Targeted Synthetic Disease Modifying Antirheumatic Drugs: Establishing a Framework to Create a "Safety Checklist".
    Skaarup L; Ingrid E; Sepriano A; Nikiphorou E; Østgård R; Lauper K; Grosse-Michaelis I; Kloppenburg M; Glintborg B; Liew DFL; Kragstrup TW
    Drug Saf; 2024 Nov; 47(11):1075-1093. PubMed ID: 39012469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of inpatient venous thromboembolism in treated patients with rheumatoid arthritis and the association with switching biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in the real-world setting.
    Liang H; Danwada R; Guo D; Curtis JR; Kilpatrick RD; Hendrickson B; Islam SS
    RMD Open; 2019; 5(2):e001013. PubMed ID: 31673413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme.
    Frisell T; Bower H; Morin M; Baecklund E; Di Giuseppe D; Delcoigne B; Feltelius N; Forsblad-d'Elia H; Lindqvist E; Lindström U; Askling J;
    Ann Rheum Dis; 2023 May; 82(5):601-610. PubMed ID: 36787994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: analysis of the Australian Rheumatology Association Database (ARAD) prospective cohort study.
    Buchbinder R; Van Doornum S; Staples M; Lassere M; March L
    BMC Musculoskelet Disord; 2015 Oct; 16():309. PubMed ID: 26481039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different risk profiles of biologic agents for new-onset psoriasis in patients with rheumatoid arthritis.
    Baganz L; Listing J; Kekow J; Eisterhues C; Wassenberg S; Zink A; Strangfeld A
    Semin Arthritis Rheum; 2020 Feb; 50(1):36-41. PubMed ID: 31350056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of malignancy associated with use of tocilizumab versus other biologics in patients with rheumatoid arthritis: A multi-database cohort study.
    Kim SC; Pawar A; Desai RJ; Solomon DH; Gale S; Bao M; Sarsour K; Schneeweiss S
    Semin Arthritis Rheum; 2019 Oct; 49(2):222-228. PubMed ID: 30967248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.